| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Chemistry, Vol 33, 2153-2163, Copyright © 1987 by American Association for Clinical Chemistry
DA Armbruster
Laboratory Services Branch, USAF School of Aerospace Medicine, Air Force Systems Command, Brooks Air Force Base, TX 78235-5301.
Glucose molecules are joined to protein molecules to form stable ketoamines, or fructosamines, through glycation, a nonenzymatic mechanism involving a labile Schiff base intermediate and the Amadori rearrangement. The amount of fructosamine in serum is increased in diabetes mellitus owing to the abnormally high concentration of sugar in blood. The concentration of fructosamine in serum thus reflects the degree of glycemic control attained by the diabetic patient and is useful in monitoring the effectiveness of therapy in diabetes over a period of several weeks, in a manner analogous to the determination of glycated hemoglobin. Of the analytical approaches used to measure fructosamine, affinity chromatography with m-aminophenylboronic acid and the nitroblue tetrazolium reduction method appear to be the most practical means for clinical chemists to assay fructosamine quickly, economically, and accurately. Fructosamine values can readily distinguish normal individuals and diabetic patients in good glycemic control from diabetics in poor control. Unlike glycated hemoglobin, which reflects the average blood sugar concentration over the past six to eight weeks, fructosamine reflects the average blood sugar concentration over the past two to three weeks. Thus a clinical advantage is that fructosamine responds more quickly to changes in therapy, thereby allowing for improved glycemic control. Used in conjunction with determinations of blood sugar and (or) of glycated hemoglobin, or by itself, the fructosamine assay can provide clinically useful information for the detection and control of diabetes.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  P. Roestenberg, F. A. van Nieuwenhoven, J. A. Joles, C. Trischberger, P. P. Martens, N. Oliver, J. Aten, J. W. Hoppener, and R. Goldschmeding Temporal expression profile and distribution pattern indicate a role of connective tissue growth factor (CTGF/CCN-2) in diabetic nephropathy in mice Am J Physiol Renal Physiol, June 1, 2006; 290(6): F1344 - F1354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Demiot, M. Tartas, B. Fromy, P. Abraham, J. L. Saumet, and D. Sigaudo-Roussel Aldose reductase pathway inhibition improved vascular and C-fiber functions, allowing for pressure-induced vasodilation restoration during severe diabetic neuropathy. Diabetes, May 1, 2006; 55(5): 1478 - 1483. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Demiot, B. Fromy, J. L. Saumet, and D. Sigaudo-Roussel Preservation of pressure-induced cutaneous vasodilation by limiting oxidative stress in short-term diabetic mice Cardiovasc Res, January 1, 2006; 69(1): 245 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wang, C. Dou, C. Yuan, and A. Datta Development of an Automated Enzymatic Assay for the Determination of Glycated Serum Protein in Human Serum Clin. Chem., October 1, 2005; 51(10): 1991 - 1992. [Full Text] [PDF]
|
|
|
|
 |
|
 S. M Kosecki, P. T Rodgers, and M. B Adams Glycemic Monitoring in Diabetics with Sickle Cell Plus {beta}-Thalassemia Hemoglobinopathy Ann. Pharmacother., September 1, 2005; 39(9): 1557 - 1560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 How to reconcile high blood glucose with normal A1C DOC News, June 1, 2005; 2(6): 5 - 5. [Full Text]
|
|
|
|
 |
|
 D. E. Goldstein, R. R. Little, R. A. Lorenz, J. I. Malone, D. Nathan, C. M. Peterson, and D. B. Sacks Tests of Glycemia in Diabetes Diabetes Care, July 1, 2004; 27(7): 1761 - 1773. [Full Text] [PDF]
|
|
|
|
|
|
F. Collard, G. Delpierre, V. Stroobant, G. Matthijs, and E. Van Schaftingen A Mammalian Protein Homologous to Fructosamine-3-Kinase Is a Ketosamine-3-Kinase Acting on Psicosamines and Ribulosamines but not on Fructosamines Diabetes, December 1, 2003; 52(12): 2888 - 2895. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Fujita, L. K. Curtiss, I. Sakurabayashi, F. Kameko, N. Okumura, F. Terasawa, M. Tozuka, and T. Katsuyama Identification and Properties of Glycated Monoclonal IgA That Affect the Fructosamine Assay Clin. Chem., May 1, 2003; 49(5): 805 - 808. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Wiame, G. Delpierre, F. Collard, and E. Van Schaftingen Identification of a Pathway for the Utilization of the Amadori Product Fructoselysine in Escherichia coli J. Biol. Chem., November 1, 2002; 277(45): 42523 - 42529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z.-M. Bian, V. M. Elner, A. Yoshida, S. L. Kunkel, and S. G. Elner Signaling Pathways for Glycated Human Serum Albumin-Induced IL-8 and MCP-1 Secretion in Human RPE Cells Invest. Ophthalmol. Vis. Sci., June 1, 2001; 42(7): 1660 - 1668. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. Levi and M. J. Werman Long-Term Fructose Consumption Accelerates Glycation and Several Age-Related Variables in Male Rats J. Nutr., September 1, 1998; 128(9): 1442 - 1449. [Abstract] [Full Text]
|
|
|
|
|
|
G. Halwachs-Baumann, S. Katzensteiner, W. Schnedl, P. Purstner, T. Pieber, and M. Wilders-Truschnig Comparative evaluation of three assay systems for automated determination of hemoglobin A1c Clin. Chem., March 1, 1997; 43(3): 511 - 517. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
